JHS Svendgaard Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 18, 2025, 9:37 am

Quick Insight

Based on the data provided for JHS Svendgaard Laboratories Ltd, the company's intrinsic value and share price analysis reveal a price of 11.6 with a market capitalization of 99.4 crore. With a P/E ratio not specified, a ROE of 10.8%, and a ROCE of 5.19%, the company's operational performance seems moderate. The low OPM of 7.08% and a negative net profit of -20 crore raise concerns about profitability. While promoters hold a significant stake at 34.56%, institutional ownership from FIIs is minimal at 1.59%. The company's low P/BV ratio of 0.75x and an ICR of 7.34x indicate potential undervaluation and strong debt coverage, respectively. In conclusion, investors should carefully consider the company's financial health and growth prospects before making any investment decisions.

Competitors of JHS Svendgaard Laboratories Ltd

All Competitor Stocks of JHS Svendgaard Laboratories Ltd

Quarterly Result

Last Updated: August 20, 2025, 8:40 am

Below is a detailed analysis of the quarterly data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 23.45 Cr.. The value appears to be declining and may need further review. It has decreased from 25.17 Cr. (Mar 2025) to 23.45 Cr., marking a decrease of 1.72 Cr..
• For Expenses, as of Jun 2025, the value is 21.79 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 30.55 Cr. (Mar 2025) to 21.79 Cr., marking a decrease of 8.76 Cr..
• For Operating Profit, as of Jun 2025, the value is 1.66 Cr.. The value appears strong and on an upward trend. It has increased from -5.38 Cr. (Mar 2025) to 1.66 Cr., marking an increase of 7.04 Cr..
• For OPM %, as of Jun 2025, the value is 7.08%. The value appears strong and on an upward trend. It has increased from -21.37% (Mar 2025) to 7.08%, marking an increase of 28.45%.
• For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.44 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 2.44 Cr..
• For Interest, as of Jun 2025, the value is 0.16 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.21 Cr. (Mar 2025) to 0.16 Cr., marking a decrease of 0.05 Cr..
• For Depreciation, as of Jun 2025, the value is 1.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.02 Cr. (Mar 2025) to 1.88 Cr., marking a decrease of 0.14 Cr..
• For Profit before tax, as of Jun 2025, the value is 0.62 Cr.. The value appears strong and on an upward trend. It has increased from -9.05 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 9.67 Cr..
• For Tax %, as of Jun 2025, the value is -69.35%. The value appears to be improving (decreasing) as expected. It has decreased from -23.09% (Mar 2025) to -69.35%, marking a decrease of 46.26%.
• For Net Profit, as of Jun 2025, the value is 1.06 Cr.. The value appears strong and on an upward trend. It has increased from -6.96 Cr. (Mar 2025) to 1.06 Cr., marking an increase of 8.02 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.81 (Mar 2025) to 0.12, marking an increase of 0.93.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 5:06 pm

Growth

Last Updated: September 5, 2025, 8:15 am

Balance Sheet

Last Updated: September 10, 2025, 1:54 pm

Below is a detailed analysis of the balance sheet data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 78.00 Cr. (Mar 2024) to 86.00 Cr., marking an increase of 8.00 Cr..
• For Reserves, as of Mar 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Mar 2024) to 87.00 Cr., marking a decrease of 4.00 Cr..
• For Borrowings, as of Mar 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5.00 Cr. (Mar 2024) to 6.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.00 Cr. (Mar 2024) to 25.00 Cr., marking an increase of 3.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 204.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 197.00 Cr. (Mar 2024) to 204.00 Cr., marking an increase of 7.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 90.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 90.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
• For Other Assets, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 8.00 Cr..
• For Total Assets, as of Mar 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 197.00 Cr. (Mar 2024) to 204.00 Cr., marking an increase of 7.00 Cr..

Notably, the Reserves (87.00 Cr.) exceed the Borrowings (6.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for JHS Svendgaard Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is -0.52. This value is below the healthy minimum of 5. It has increased from -2.34 (Mar 23) to -0.52, marking an increase of 1.82.
• For Diluted EPS (Rs.), as of Mar 24, the value is -0.52. This value is below the healthy minimum of 5. It has increased from -2.34 (Mar 23) to -0.52, marking an increase of 1.82.
• For Cash EPS (Rs.), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 3. It has increased from -1.43 (Mar 23) to 0.29, marking an increase of 1.72.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 21.67. It has decreased from 27.78 (Mar 23) to 21.67, marking a decrease of 6.11.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 21.67. It has decreased from 27.78 (Mar 23) to 21.67, marking a decrease of 6.11.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 9.03. It has decreased from 14.82 (Mar 23) to 9.03, marking a decrease of 5.79.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 0.43. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.43, marking a decrease of 0.38.
• For PBIT / Share (Rs.), as of Mar 24, the value is -0.37. This value is below the healthy minimum of 0. It has decreased from -0.33 (Mar 23) to -0.37, marking a decrease of 0.04.
• For PBT / Share (Rs.), as of Mar 24, the value is -0.43. This value is below the healthy minimum of 0. It has increased from -3.37 (Mar 23) to -0.43, marking an increase of 2.94.
• For Net Profit / Share (Rs.), as of Mar 24, the value is -0.51. This value is below the healthy minimum of 2. It has increased from -2.58 (Mar 23) to -0.51, marking an increase of 2.07.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -0.51. This value is below the healthy minimum of 2. It has increased from -2.38 (Mar 23) to -0.51, marking an increase of 1.87.
• For PBDIT Margin (%), as of Mar 24, the value is 4.77. This value is below the healthy minimum of 10. It has decreased from 5.50 (Mar 23) to 4.77, marking a decrease of 0.73.
• For PBIT Margin (%), as of Mar 24, the value is -4.19. This value is below the healthy minimum of 10. It has decreased from -2.25 (Mar 23) to -4.19, marking a decrease of 1.94.
• For PBT Margin (%), as of Mar 24, the value is -4.84. This value is below the healthy minimum of 10. It has increased from -22.70 (Mar 23) to -4.84, marking an increase of 17.86.
• For Net Profit Margin (%), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 5. It has increased from -17.43 (Mar 23) to -5.73, marking an increase of 11.70.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 8. It has increased from -16.07 (Mar 23) to -5.73, marking an increase of 10.34.
• For Return on Networth / Equity (%), as of Mar 24, the value is -2.38. This value is below the healthy minimum of 15. It has increased from -8.96 (Mar 23) to -2.38, marking an increase of 6.58.
• For Return on Capital Employeed (%), as of Mar 24, the value is -1.70. This value is below the healthy minimum of 10. It has decreased from -1.09 (Mar 23) to -1.70, marking a decrease of 0.61.
• For Return On Assets (%), as of Mar 24, the value is -2.05. This value is below the healthy minimum of 5. It has increased from -6.54 (Mar 23) to -2.05, marking an increase of 4.49.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.02. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.02, marking an increase of 0.02.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.32. It has decreased from 0.41 (Mar 23) to 0.32, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 24, the value is 1.87. This value is within the healthy range. It has decreased from 2.36 (Mar 23) to 1.87, marking a decrease of 0.49.
• For Quick Ratio (X), as of Mar 24, the value is 1.33. This value is within the healthy range. It has decreased from 2.00 (Mar 23) to 1.33, marking a decrease of 0.67.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.11. This value is below the healthy minimum of 4. It has decreased from 4.36 (Mar 23) to 3.11, marking a decrease of 1.25.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 7.34. This value is within the healthy range. It has increased from 5.09 (Mar 23) to 7.34, marking an increase of 2.25.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -7.82. This value is below the healthy minimum of 3. It has decreased from 2.78 (Mar 23) to -7.82, marking a decrease of 10.60.
• For Enterprise Value (Cr.), as of Mar 24, the value is 121.69. It has increased from 70.51 (Mar 23) to 121.69, marking an increase of 51.18.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.72. This value is within the healthy range. It has increased from 0.73 (Mar 23) to 1.72, marking an increase of 0.99.
• For EV / EBITDA (X), as of Mar 24, the value is 36.03. This value exceeds the healthy maximum of 15. It has increased from 13.31 (Mar 23) to 36.03, marking an increase of 22.72.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.81. This value is within the healthy range. It has increased from 1.06 (Mar 23) to 1.81, marking an increase of 0.75.
• For Price / BV (X), as of Mar 24, the value is 0.75. This value is below the healthy minimum of 1. It has increased from 0.59 (Mar 23) to 0.75, marking an increase of 0.16.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.81. This value is within the healthy range. It has increased from 1.06 (Mar 23) to 1.81, marking an increase of 0.75.
• For EarningsYield, as of Mar 24, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.15 (Mar 23) to -0.03, marking an increase of 0.12.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness